Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalmefene plus hydromorphone for postoperative IV-PCA after lumbar fracture fixation
ChiCTR2200063287Phase 4Not yet recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of nalmefene and hydromorphone in lumbar fracture and postoperative pain (3 arms), sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoint: Numeric Rating Scale (NRS) pain score. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
nalmefenehydromorphone
03
Conditions
lumbar fracturepostoperative pain
Beyond the preview
Go deeper on ChiCTR2200063287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063287.